About AVT
Browse Articles
Authors
Customer Services

From the first issue of Volume 26 (2021) Antiviral Therapy will be published by SAGE Publishing.

Please note that the journal is running later than expected due to COVID-19.

During the transition, you can still access content to which you have subscribed via the AVT website. Content will be available to access via the SAGE Journals platform in Summer 2021. https://uk.sagepub.com/en-gb/eur/antiviraltherapy.

If you have any questions relating to the transfer, please contact journaltransitions@sagepub.com

From the first issue of Volume 26 (2021) Antiviral Therapy will be published by SAGE Publishing.

Subscriptions Please note that Antiviral Therapy is running later than expected due to COVID-19.

All subscription queries should be sent to subscriptions@sagepub.co.uk

Orders via subscription agents
If you are using a subscription agent, please instruct your agent as usual. We are notifying all subscription agents of this change of publisher and they will be able to handle your query.

Pricing enquiries 2021 Antiviral Therapy pricing set by International Medical Press will be honoured.

From the first issue of Volume 26 (2021) Antiviral Therapy will be published by SAGE Publishing.

Please continue to submit your manuscripts to the AVT ScholarOne site (https://mc.manuscriptcentral.com/avt)

For papers already in peer-review, you will be informed of a decision as soon as possible. All accepted papers not assigned to a 2020 issue will now be published by SAGE.

Browse Articles

Additional files for manuscripts published before Volume 14 Issue 6 can be found via the abstract link.

Articles published electronically ahead of print and our archive from Volume 4 Issue 1 to Volume 24 Issue 7 can be found below. Articles published earlier will be made available as soon as possible. If you require an article that cannot be found below, please contact the Editorial Office.

Currently showing:   
Displaying 18 results:

Free
Workshop report

HIV and hepatitis virus resistance to antivirals: review of data from the XIX International HIV and Hepatitis Virus Drug Resistance Workshop and Curative Strategies

Mark Mascolini, John W Mellors, Douglas D Richman, Charles AB Boucher, Brendan A Larder

Antiviral Therapy 2011; 16:263-286


Free
Case report

Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient

Sarita D Boyd, Frank Maldarelli, Irini Sereti, G Laissa Ouedraogo, Catherine A Rehm, Valerie Boltz, Diana Shoemaker, Alice K Pau

Antiviral Therapy 2011; 16:257-261


Free
Case report

Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy

Benjamin Young, Signe Fransen, Kenneth S Greenberg, Amy Thomas, Sharon Martens, Marty St Clair, Christos J Petropoulos, Belinda Ha

Antiviral Therapy 2011; 16:253-256


Free
Case report

Interaction between antiretroviral drugs and acenocoumarol

Marieke EB Welzen, Guido EL van den Berk, Raph L Hamers, David M Burger

Antiviral Therapy 2011; 16:249-252


Free
Original article

Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus pneumonia

Nelson Lee, Paul KS Chan, Chun Kwok Wong, Ka-Tak Wong, Kin-Wing Choi, Gavin M Joynt, Philip Lam, Martin CW Chan, Bonnie CK Wong, Grace CY Lui, Winnie WY Sin, Rity YK Wong, Wai-Yip Lam, Apple CM Yeung, Ting-Fan Leung, Hing-Yu So, Alex WY Yu, Joseph JY Sung, David SC Hui

Antiviral Therapy 2011; 16:237-247


Free
Original article

HCV core gene polymorphisms correlate with liver fibrosis but not sustained virological response in patients with genotype 1 infection

Shih–Jer Hsu, Ching-Sheng Hsu, Chen-Hua Liu, Chun-Jen Liu, Chi-Ling Chen, Pei-Jer Chen, Ding-Shinn Chen, Jia-Horng Kao

Antiviral Therapy 2011; 16:227-235


Free
Original article

Risk factors for fatality in HIV-infected patients with dideoxynucleoside-induced severe hyperlactataemia or lactic acidosis

Alejandro Arenas-Pinto, Alison Grant, Krishnan Bhaskaran, Andrew Copas, Andrew Carr, Signe W Worm, Esteban Martinez, Peter Reiss, David Dunn, Rainer Weber, Jennifer Hoy, Ian Weller, the Lactic Acidosis International Study Group

Antiviral Therapy 2011; 16:219-226


Free
Original article

Role of regulatory T-cells in immunization strategies involving a recombinant alphavirus vector system

Mateusz Walczak, Joke Regts, Antoon JM van Oosterhout, Louis Boon, Jan Wilschut, Hans W Nijman, Toos Daemen

Antiviral Therapy 2011; 16:207-218


Free
Original article

Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV–HBV-coinfected patients

Vincent Thibault, Hind Stitou, Nathalie Desire, Marc-Antoine Valantin, Roland Tubiana, Christine Katlama

Antiviral Therapy 2011; 16:199-205


Free
Original article

Successful efavirenz dose reduction guided by therapeutic drug monitoring

Aurélie Fayet Mello, Thierry Buclin, Laurent A Decosterd, Cécile Delhumeau, Julia di Iulio, Alessandra Fleurent, Marie-Paule Schneider, Matthias Cavassini, Amalio Telenti, Bernard Hirschel, Alexandra Calmy

Antiviral Therapy 2011; 16:189-197


Page:
Copyright © 2021 Nucleus Holdings Ltd. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.